Clinical Research Directory
Browse clinical research sites, groups, and studies.
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
Sponsor: NYU Langone Health
Summary
This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.
Official title: A Randomized Controlled Trial Comparing the Efficacy of Topical Vaginal Estrogen Versus Topical Vaginal Estrogen Plus Via, a Hyaluronic Acid-Based Vaginal Moisturizer, in the Treatment of Genitourinary Syndrome of Menopause
Key Details
Gender
FEMALE
Age Range
45 Years - Any
Study Type
INTERVENTIONAL
Enrollment
196
Start Date
2025-07-01
Completion Date
2026-05-01
Last Updated
2025-06-26
Healthy Volunteers
No
Interventions
Vaginal estrogen tablet
The dosage of the vaginal estrogen will be one 10mcg tablet administered vaginally nightly for 2 weeks, then administered vaginally twice weekly for 14 weeks.
Via Solv Wellness (Hyaluronic Acid Therapy)
The dosage of Via will be a pea-sized amount applied vaginally along the vaginal and vulvar walls nightly for 16 weeks.
Locations (1)
NYU Langone Health
New York, New York, United States